Category: 166591-85-1

New learning discoveries about 166591-85-1

The synthetic route of 166591-85-1 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.166591-85-1,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid,as a common compound, the synthetic route is as follows.,166591-85-1

2,3-Dihydro-1H-inden-2-amine (0.240 g, 1.803 mmol) was added to a solution of 2-{tert- butoxycarbonyl)-l,2,3,4-tetrahydroisoquinoline-l-carboxylic acid (0.S g, 1.803 mmol) in DCM (10 mL) then EDC.HC1 (0.519 g, 2.70 mmol), HOAT (0.446 g, 2.70 mmol) and TEA (0.627 mL, S.41 mmol) were added under nitrogen. The reaction was stirred at room temperature for 18 h. The reaction mixture was washed with water, IN HCI, and sat. NaHCCh, dried (MgS04) and concentrated in vacuo to afford the title compound. (0870) ‘H NMR (400 MHz, DMSO-d6) delta ppm 1.28 – 1.51 (m, 9 H) 2.58 – 3.26 (m, 6 H) 3.46 – 3.63 (m, 1 H) 3.74 – 3.93 (m, 1 H) 4.28 – 4.47 (m, 1 H) 5.20 (s, 1 H) 7.05 – 7.30 (m, 7 H) 7.36 – 7.51 (m, l H) 8.57 (m, 1 H) (0871) MS ES+: 293 (M-BOC)

The synthetic route of 166591-85-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; LIWICKI, Gemma; MACK, Stephen; STEPHENSON, Anne; TEALL, Martin; WHITE, Kathryn; (168 pag.)WO2018/47983; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

Introduction of a new synthetic route about 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid

With the rapid development of chemical substances, we look forward to future research findings about 166591-85-1

2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid, cas is 166591-85-1, it is a common heterocyclic compound, the tetrahydroisoquinoline compound, its synthesis route is as follows.

T3P (50% in EtOAc) (3.22 mL, 5.41 mmol) was added to a solution of 2-(/eri- butoxycarbonyl)-l,2,3,4-tetrahydroisoquinoline-l-carboxylic acid (1.00 g, 3.61 mmol),(trans)- l-methoxy-2,3-dihydro-1H-inden-2-amine (Intermediate 2, 0.647 g, 3.97 mmol) and TEA (0.754 mL, 5.41 mmol) in DCM (20 mL). The reaction was stirred at room temperature for 1.5 h. The mixture was partitioned between DCM and saturated NaHCCh, dried (phase separator) and concentrated in vacuo. The crude product was purified by column chromatography on silica, eluted with 0-50% EtOAc/petroleum ether to afford the title compound. ‘Eta NMR (300 MHz, DMSO-4s) delta ppm 1.34 – 1.50 (m, 9 H), 2.66 – 2.83 (m, 2 H), 2.94 – 3.09 (m, 1 H), 3.13 – 3.28 (m, 3 H), 3.34 – 3.39 (m, 1 H), 3.45 – 3.66 (m, 1 H), 3.82 – 3.96 (m, 1 H), 4.20 – 4.37 (m, 1 H), 4.60 – 4.74 (m, 1 H), 5.17 – 5.41 (m, 1 H), 7.13 – 7.37 (m, 7 H), 7.40 – 7.59 (m, 1 H), 8.57 – 8.80 (m, 1 H) (0622) MS ES+: 445 (M+Na), 166591-85-1

With the rapid development of chemical substances, we look forward to future research findings about 166591-85-1

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; LIWICKI, Gemma; MACK, Stephen; STEPHENSON, Anne; TEALL, Martin; WHITE, Kathryn; (168 pag.)WO2018/47983; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

Brief introduction of 166591-85-1

#N/A

166591-85-1, 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

T3P (50% in EtOAc) (3.22 mL, 5.41 mmol) was added to a solution of 2-(/eri- butoxycarbonyl)-l,2,3,4-tetrahydroisoquinoline-l-carboxylic acid (1.00 g, 3.61 mmol),(trans)- l-methoxy-2,3-dihydro-1H-inden-2-amine (Intermediate 2, 0.647 g, 3.97 mmol) and TEA (0.754 mL, 5.41 mmol) in DCM (20 mL). The reaction was stirred at room temperature for 1.5 h. The mixture was partitioned between DCM and saturated NaHCCh, dried (phase separator) and concentrated in vacuo. The crude product was purified by column chromatography on silica, eluted with 0-50% EtOAc/petroleum ether to afford the title compound. ‘Eta NMR (300 MHz, DMSO-4s) delta ppm 1.34 – 1.50 (m, 9 H), 2.66 – 2.83 (m, 2 H), 2.94 – 3.09 (m, 1 H), 3.13 – 3.28 (m, 3 H), 3.34 – 3.39 (m, 1 H), 3.45 – 3.66 (m, 1 H), 3.82 – 3.96 (m, 1 H), 4.20 – 4.37 (m, 1 H), 4.60 – 4.74 (m, 1 H), 5.17 – 5.41 (m, 1 H), 7.13 – 7.37 (m, 7 H), 7.40 – 7.59 (m, 1 H), 8.57 – 8.80 (m, 1 H) (0622) MS ES+: 445 (M+Na)

#N/A

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; LIWICKI, Gemma; MACK, Stephen; STEPHENSON, Anne; TEALL, Martin; WHITE, Kathryn; (168 pag.)WO2018/47983; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem